Figure 8. Anti-TNFR1 monoclonal antibodies attenuated the clinical course of EAN in WT mice.

EAN was induced in WT mice by immunization with P0 peptide 180–199 in combination with FCA. Anti-TNFR1 monoclonal antibodies were administered intravenously at the dose of 200 µg/kg body weight on days −1, 3, and 7 p.i., respectively. Sex- and age-matched mice from the same strain received 0.9% saline as controls. Using a blinded protocol, two different examiners evaluated clinical severity of EAN mice immediately before immunization (day 0 p.i.) and thereafter every two days until day 35 p.i. From day 7 p.i., the clinical severity was significantly milder in the anti-TNFR1-treated group than in the control group, except on day 11 p.i., when the difference did not reach statistical significance. Data are presented as mean value ± SD of one representative out of two independent experiments (n = 5 in each group). ** p<0.01.